Light Might Reveal Hidden Threat in Premature Babies
The Accidental Discovery That Shone a Light on Tiny Bellies
The journey toward this potential breakthrough began not with a grand plan to invent a new medical device, but with a simple observation about the nature of premature infants. Their skin, unlike that of full-term babies, is remarkably thin and partially transparent to certain wavelengths of light. This physical characteristic, which had been known for years, was not typically seen as a diagnostic opportunity. It was just a fact of neonatal physiology, a footnote in medical textbooks about the fragility of these smallest patients. The idea of using this transparency as a window into the body was not the starting point; it was a realization that emerged from considering the problem from a different angle.
Pediatric surgeon Seth Goldstein of Lurie Children’s Hospital of Chicago was the one to connect this known fact with a devastating, hard-to-detect disease. Necrotizing enterocolitis, or NEC, is a life-threatening inflammation of the intestine that primarily strikes premature babies. It is a disease that can appear with almost no warning, turning a stable infant into a critical patient within hours. The disease is one of the most feared diagnoses in neonatal intensive care units, a place already filled with anxiety and high-stakes decisions. The challenge has always been that by the time the classic symptoms appear, the disease has often already taken hold, making treatment more difficult and the outcome more uncertain.
Goldstein’s insight was built on a chain of logic that started with the babies’ transparent skin. He knew that NEC, as it progresses, causes the intestines to darken as they lose their blood supply. This color change is a physical sign of the tissue dying, but it is hidden inside the body. The question he posed was simple: if the skin is so thin that light can pass through it, could that same light be used to see the color changes happening in the gut below? This was not a search for a new molecule or a genetic marker, but a return to the most basic of medical observations — looking at the color of tissue to judge its health.
The path forward was not about inventing a new type of light, but about using the light that already exists in a new way. The researchers began to explore whether infrared and visible light, shone on the abdomen, could reveal the subtle color shifts that signal the onset of NEC. This approach was fundamentally different from other diagnostic methods, which rely on blood tests or X-rays. It was a direct, non-invasive way to look at the organ itself, using the body’s own optical properties as a signal. The breakthrough was not a new object but a new connection — a bridge between a known physical trait and an unsolved clinical problem
The Next Step: From a Small Pilot to a Larger Test
The initial results of this optical approach have been promising enough to warrant a much larger investigation. A pilot study involving 96 premature infants showed that the scanning technique was safe and feasible to use in a clinical setting. In this small group, the scans correctly identified all 10 babies who developed NEC. [1] This detection rate is encouraging, but the researchers acknowledge its limitations. The study also returned a significant number of false positives, meaning the scan flagged some babies who did not actually have the disease. This is a critical issue, as false alarms could lead to unnecessary treatments.
The next step, which the researchers themselves have named, is to launch a large test of the technology within the next year. This larger study is designed to answer the questions that the pilot study could not. The primary goal is to see if the approach can detect NEC before any symptoms appear. In the pilot, the scans were taken at certain intervals; in the future study, the plan is to scan a much larger group of babies more regularly. This would allow the team to see if the light-based signal changes before the clinical signs of NEC, such as a distended abdomen, become apparent to a doctor or nurse.
The team previously demonstrated that this kind of early detection is possible in a study on mice In that animal model, the mice were scanned daily, and the researchers were able to observe the changes in the light signal before the disease became severe. This proof-of-concept in animals gives them confidence that the same could be true for human infants, but it is not a guarantee. The leap from mice to humans is a significant one, and the upcoming larger trial is designed to bridge that gap. The researchers are not just repeating their pilot study; they are testing a more ambitious hypothesis: that this tool can predict NEC before it manifests.
Beyond the clinical trial, the team is also working on a parallel project to make the technology more practical. They are developing a low-cost, handheld device that could be used easily in any neonatal intensive care unit. The current probe and spectrometer setup works, but it is not something that could be placed at every bedside. A handheld device would be a step toward integrating this screening into the routine care of every premature infant. The vision is not just to have a diagnostic tool, but to have one that is so simple and affordable that it becomes a standard part of the bassinet, as Goldstein puts it, “just a part of the routine.”
What This Changes and What It Leaves Open
The potential impact of this technology is best understood when compared to the current reality of treating NEC. The disease has a mortality rate of over 20 percent, and its onset is sudden. [1] It is estimated to affect up to five percent of all premature infants, with the risk rising to 10 percent for those born weighing less than 1,500 grams. Currently, early-stage NEC can be treated with antibiotics and by switching a newborn to intravenous feeding. However, once the disease becomes severe, it often requires surgery to remove part of the intestine. The difference between these two outcomes is often a matter of time.
This is where the new light-based scan could change the equation If it can detect NEC in its earliest stages, or even before symptoms appear, it could give doctors the crucial window they need to intervene with non-surgical treatments. This would not only be less invasive for the baby, but it could also reduce the mortality rate and the long-term complications associated with severe NEC. The technology is not a cure, but it could be a powerful early warning system. It changes the question from “how do we treat this severe disease?” to “how do we catch this disease before it becomes severe?”
However, the technology is not without its skeptics, and the source of their concern is the false positives. Ravi Patel, director of neonatal clinical research at Emory University in Atlanta, notes that the pilot study includes “too few cases to know how it would perform in the real world.” [2] He also raises the concern that false positives could lead to overtreatment. If a baby is flagged as potentially having NEC, but does not, they might receive antibiotics or other interventions they do not need. This is a real risk, and it is one that the larger trial will need to address by refining the machine learning model that analyzes the light signals.
Patel is cautious but not dismissive, saying the technology is “worth looking into more.” His perspective is shaped by the fact that NEC-specific treatments remain so limited. As he points out, “There’s zero drugs that are available, once a baby develops NEC, to prevent the worsening of the disease.” This is the stark reality that makes early detection so crucial. The light-based scan is one of several new avenues being pursued to prevent NEC, alongside developing new probiotics and looking for biomarkers in the blood. This new tool does not solve the entire problem, but it addresses a critical gap: the ability to see what is happening inside the body without waiting for the disease to become catastrophic